Among the 93 patients who received second post-T-DXd treatment, 2 (2.2%) experienced ILD recurrence.<h4>Conclusion</h4>These findings highlight the importance of early ILD detection and management so patients can receive, and potentially benefit from, subsequent anti-HER2 targeted therapies. This evidence concerns the gene ERBB2 and interstitial lung disease.